Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.…
Intensity (INTS) Q3 2026 Earnings Call Transcript
Intensity Therapeutics (NASDAQ: INTS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 5 employees.
The shares were at 2.480 USD on 20 November 2026, down 78.2% over 52 weeks. Its 52-week range is 2.280 USD to 15.00 USD: the price is 83.5% below the high and 8.8% above the low.
Its market capitalisation is 8.19M USD.
Intensity Therapeutics reports return on equity of -97.7% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 8.41M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.